The most common adverse reactions in adult patients with prurigo nodularis (≥2%, pooled safety data across PRIME and PRIME2) are nasopharyngitis (5% for DUPIXENT vs 2% for placebo); conjunctivitis (4% for DUPIXENT vs 1% for placebo); herpes infection (3% for DUPIXENT vs 0% for placebo); dizziness (3% for DUPIXENT vs 1% for placebo); myalgia (3% for DUPIXENT vs 1% for placebo); and diarrhea (3% for DUPIXENT vs 1% for placebo).1
No patients treated with DUPIXENT (0%) discontinued treatment due to adverse events vs 3% with placebo. Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic infection resolves in a patient who does not respond to anti-helminth treatment.1